Bradley L. Campbell Sells 7,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total value of $79,500.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $9,398,532.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Amicus Therapeutics Price Performance

Shares of FOLD stock opened at $10.60 on Friday. The company has a market capitalization of $3.14 billion, a P/E ratio of -21.63 and a beta of 0.69. The company’s 50-day simple moving average is $11.11 and its two-hundred day simple moving average is $10.64. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57. The company has a debt-to-equity ratio of 2.93, a current ratio of 2.75 and a quick ratio of 2.26.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). The firm had revenue of $126.67 million during the quarter, compared to analyst estimates of $121.21 million. Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. Amicus Therapeutics’s quarterly revenue was up 34.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.15) earnings per share. As a group, equities analysts anticipate that Amicus Therapeutics, Inc. will post -0.08 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 16th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 target price on shares of Amicus Therapeutics in a research note on Friday, September 20th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $17.00.

Institutional Trading of Amicus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Headlands Technologies LLC purchased a new position in Amicus Therapeutics during the 2nd quarter valued at about $89,000. Sage Capital Advisors llc purchased a new stake in Amicus Therapeutics during the second quarter worth $103,000. Sanctuary Advisors LLC purchased a new stake in Amicus Therapeutics during the second quarter worth $138,000. EntryPoint Capital LLC increased its holdings in shares of Amicus Therapeutics by 278.8% in the 1st quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock valued at $156,000 after acquiring an additional 9,729 shares during the period. Finally, Old Well Partners LLC purchased a new position in shares of Amicus Therapeutics in the 4th quarter valued at $180,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.